THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 113 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $504,107 | -6.7% | 48,706 | -2.1% | 0.00% | 0.0% |
| Q1 2023 | $540,070 | -29.5% | 49,776 | -27.1% | 0.00% | -33.3% |
| Q4 2022 | $766,090 | +38.0% | 68,279 | +24.8% | 0.00% | 0.0% |
| Q3 2022 | $555,000 | +222.7% | 54,726 | +188.3% | 0.00% | +200.0% |
| Q2 2022 | $172,000 | -2.3% | 18,985 | +18.9% | 0.00% | – |
| Q4 2021 | $176,000 | -32.6% | 15,971 | -54.7% | 0.00% | -100.0% |
| Q3 2021 | $261,000 | -64.6% | 35,226 | -29.4% | 0.00% | -90.0% |
| Q3 2020 | $738,000 | +196.4% | 49,919 | +321.3% | 0.01% | +150.0% |
| Q2 2020 | $249,000 | -74.3% | 11,850 | -76.1% | 0.00% | -55.6% |
| Q3 2019 | $967,000 | +5.7% | 49,622 | -11.5% | 0.01% | 0.0% |
| Q2 2019 | $915,000 | +131.6% | 56,061 | +222.1% | 0.01% | +125.0% |
| Q1 2019 | $395,000 | +41.6% | 17,405 | +41.5% | 0.00% | -76.5% |
| Q2 2016 | $279,000 | – | 12,300 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,012,226 | $60,515,510 | 8.59% |
| Irenic Capital Management LP | 2,760,948 | $23,826,981 | 6.76% |
| Newtyn Management, LLC | 1,841,560 | $15,892,663 | 3.92% |
| Weiss Asset Management LP | 7,457,060 | $64,354,428 | 3.81% |
| Park West Asset Management LLC | 1,983,251 | $17,115,456 | 1.57% |
| Baupost Group | 7,419,226 | $64,028 | 1.23% |
| Oasis Management Co Ltd. | 953,254 | $8,226,582 | 0.36% |
| Chescapmanager LLC | 287,333 | $2,479,684 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 325,985 | $2,813 | 0.24% |
| Virtus ETF Advisers LLC | 29,232 | $252,272 | 0.15% |